Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies.

Détails

ID Serval
serval:BIB_06F13E4E3F89
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies.
Périodique
Cancer Treatment Reviews
Auteur(s)
De Bari B., Filippi A.R., Mazzola R., Bonomo P., Trovò M., Livi L., Alongi F.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
41
Numéro
6
Pages
511-518
Langue
anglais
Résumé
Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease control, however the data on outcome and toxicity are derived from low quality retrospective studies, and results should be cautiously interpreted. As SABR may be associated with serious toxicity, attention should be paid for an accurate patients' selection.
Pubmed
Web of science
Création de la notice
20/07/2015 10:19
Dernière modification de la notice
20/08/2019 12:29
Données d'usage